The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes.

There have been no reports of the quantitative prediction of induction for drug-metabolizing enzymes in humans. We have tried to predict such enzyme induction in humans from in vitro data obtained using human hepatocytes. The in vitro and in vivo data on enzyme induction by inducers, such as rifampicin, phenobarbital and omeprazole, were collected from the published literature. The degree of enzyme induction in humans was compared with that predicted from in vitro data on human hepatocytes. Using the in vivo data, we calculated the hepatic intrinsic clearance of typical CYP substrates, such as midazolam and caffeine, before and after inducer treatment and estimated the induction ratios of hepatic intrinsic clearance following treatment. In the in vitro studies, the amount of mRNA or enzyme and enzyme activity in human hepatocytes, with or without an inducer, were compared and the induction ratios were estimated. The unbound mean concentration was taken as an index of drug exposure and the induction ratios in the in vivo and in vitro studies were compared. The unbound mean concentrations of inducers used in the in vitro studies were higher than those in the in vivo studies. The maximum induction ratios by inducers in the in vitro studies were higher than those in the in vivo studies. The induction ratio for rifampicin, omeprazole, troglitazone, dexamethasone and phenobarbital increased as the unbound mean concentration increased to reach a constant value. The induction of CYP3A and 1A was analyzed by the Emax model. The maximum induction ratio (Emax) and the concentration at half maximum induction (EC50) for rifampicin, omeprazole, troglitazone, dexamethasone and phenobarbital were 12.3, 0.847 micromol/L, 2.36, 0.225 micromol/L, 6.86, 0.002 micromol/L, 8.30, 9.32 micromol/L, and 7.62, 58.4 micromol/L, respectively. The Emax and EC50 of omeprazole for CYP1A were 12.02 and 0.075 micromol/L, respectively. The predicted induction ratio of all those inducers, except for omeprazole, based on the Emax and EC50 values obtained from the in vitro data were similar to the observed values. On the whole, a good correlation between the observed and predicted induction ratio of omeprazole was observed (r=0.768, p<0.05), although the predicted induction ratio was higher than the observed value. In conclusion, the present study suggests that it is possible to predict quantitatively the CYP3A enzyme induction from hepatocyte data.

[1]  J. Domergue,et al.  Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. , 1994, The Journal of pharmacology and experimental therapeutics.

[2]  I. Roots,et al.  Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test , 1994, Clinical pharmacology and therapeutics.

[3]  P. Neuvonen,et al.  Rifampin drastically reduces plasma concentrations and effects of oral midazolam , 1996, Clinical pharmacology and therapeutics.

[4]  P. Maurel,et al.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. , 1990, Gastroenterology.

[5]  R Ohlsson,et al.  Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Lesko,et al.  Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  P. Neuvonen,et al.  Rifampin reduces plasma concentrations and effects of zolpidem , 1997, Clinical pharmacology and therapeutics.

[8]  U. Mansmann,et al.  Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. , 1997, International journal of clinical pharmacology and therapeutics.

[9]  R. Bergstrand,et al.  Omeprazole treatment does not affect the metabolism of caffeine. , 1991, Gastroenterology.

[10]  H. Kusuhara,et al.  The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.

[11]  R. Fisher,et al.  Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[12]  G. Yee,et al.  Pharmacokinetic Drug Interactions with Cyclosporin (Part I) , 1990, Clinical pharmacokinetics.

[13]  Sean Kim,et al.  CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. Wrighton,et al.  The use of human hepatocyte cultures to study the induction of cytochrome P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[15]  L. Moore,et al.  Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.

[16]  A. Li,et al.  Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. , 1997, Chemico-biological interactions.

[17]  P. Neuvonen,et al.  The effect of dexamethasone on the pharmacokinetics of triazolam. , 1998, Pharmacology & toxicology.

[18]  G. Kaatz,et al.  Enzyme induction by phenobarbitone and vitamin K1 disposition in man. , 1984, British journal of clinical pharmacology.

[19]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[20]  P. Maurel,et al.  Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.

[21]  J. Miners,et al.  Verapamil disposition--effects of sulphinpyrazone and cimetidine. , 1985, British journal of clinical pharmacology.

[22]  E. Perucca,et al.  Effect of low‐dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects [letter] , 1981 .

[23]  J. Brockmöller,et al.  Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[24]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[25]  G. Yee,et al.  Pharmacokinetic Drug Interactions with Cyclosporin (Part II) , 1990, Clinical pharmacokinetics.

[26]  A. Li,et al.  Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. , 1997, Chemico-biological interactions.

[27]  A. Li,et al.  An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. , 1998, Chemico-biological interactions.

[28]  U. Hofmann,et al.  Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone , 2000, Clinical pharmacology and therapeutics.

[29]  I. Roots,et al.  Specific and dose‐dependent enzyme induction by omeprazole in human beings , 1994, Hepatology.

[30]  L. Benet,et al.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.

[31]  S. Carruthers,et al.  Quinidine-rifampin interaction. , 1981, The New England journal of medicine.

[32]  D. Greenblatt,et al.  In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.

[33]  D. Waxman,et al.  P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. , 1999, Archives of biochemistry and biophysics.

[34]  J. S. Sidhu,et al.  Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures. , 1998, Biochemical pharmacology.

[35]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[36]  T. Tomson,et al.  Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. , 2003, British journal of clinical pharmacology.

[37]  A. Li,et al.  Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. , 1995, The Journal of pharmacology and experimental therapeutics.

[38]  M. Fromm,et al.  The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[39]  S. J. Kovacs,et al.  Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction , 1999, Journal of clinical pharmacology.

[40]  T. Izumi,et al.  Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. , 1996, The Journal of pharmacology and experimental therapeutics.

[41]  E. Perucca,et al.  Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects. , 1981, British journal of clinical pharmacology.

[42]  S. Adams,et al.  The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin , 1997, Clinical pharmacology and therapeutics.

[43]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[44]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[45]  M. Rowland,et al.  Cyclosporin-phenytoin interaction: re-evaluation using metabolite data. , 1987, British journal of clinical pharmacology.

[46]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[47]  S. Wrighton,et al.  Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. , 1998, Archives of biochemistry and biophysics.

[48]  B. K. Park,et al.  Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin , 1979, European Journal of Clinical Pharmacology.

[49]  P. Neuvonen,et al.  Triazolam is ineffective in patients taking rifampin , 1997, Clinical pharmacology and therapeutics.

[50]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[51]  C. Loi,et al.  Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol. , 1998, Journal of clinical pharmacology.